Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conventional vs Hypofractionated RT + Temozolomide in Elderly Glioblastoma
NCT05439278Phase 3Recruiting
- Sponsor
- Severance Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Severance Hospital. Primary endpoint: Overall Survival at 2 years. Started Feb 2025; status: recruiting.
Beyond the preview
Go deeper on NCT05439278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05439278.